Crossover Comparison of Maximum Dose Glyburide and Glipizide

Simcic, Kenneth J.; McDermott, Michael T.; White, Jeffery; Kidd, Gerald S.

doi:10.1097/00007611-199106000-00017

Southern Medical Journal

1991

DOI: 10.1097/00007611-199106000-00017

|View full text |Cite

Crossover Comparison of Maximum Dose Glyburide and Glipizide

Kenneth J. Simcic

Michael T. McDermott²,

Jeffery White³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1992

2004

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary mechanism is stimulation of insulin secretion (1)(2)(3)(4)(5), but insulin sensitivity may also be enhanced (6)(7)(8)(9)(10)(11)(12)(13). The clinical efficacy of the two second generation SUs glipizide and glyburide has been compared in several studies (8,(14)(15)(16)(17)(18)(19)(20)(21)(22). However, few studies have been doubleblind and placebo-controlled, and many have used doses higher than recommended, at least in Europe.…”

mentioning

confidence: 99%

Long-Term Randomized Placebo-Controlled Double-Blind Therapeutic Comparison of Glipizide and Glyburide: Glycemic control and insulin secretion during 15 months

Birkeland¹,

Furuseth²,

Melander³

et al. 1994

Diabetes Care

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Long-Term Randomized Placebo-Controlled Double-Blind Therapeutic Comparison of Glipizide and Glyburide: Glycemic control and insulin secretion during 15 months

Birkeland¹,

Furuseth²,

Melander³

et al. 1994

Diabetes Care

View full text Add to dashboard Cite

show abstract

Pharmacotherapy of Oral Hypoglycemic Agents

Miyahara

1973

Clin-Alert

View full text Add to dashboard Cite

The use of sulfonylurea in conjunction with a diet and exercise regimen continues to be the primary treatment modality for obese type II diabetics in the United States. These agents work to lower plasma glucose by several proposed mechanisms. Pancreatic mechanisms of action improve efficiency of the islet beta cells, and extrapancreatic mechanisms of action increase peripheral insulin-receptor sensitivity. Sulfonylureas are extensively metabolized in the liver. Depending on the specific agent, renally excreted metabolites with hypoglycemic activity may be produced and pose a threat to patients with impaired renal function. Accumulation of these metabolites can result in hypoglycemia, a common adverse reaction seen with the sulfonylurea. Other adverse reactions and their prevalence, presentation, and treatment are also presented. Clinically significant drug interactions of the sulfonylurea are tabulated and discussed. Because the sulfonlyureas have equivalent efficacy to each other, proper agent selection must be based on the metabolism and excretion characteristics, adverse reaction potential, and concurrent drug profile of the patient for whom the sulfonylurea is being selected. In patients who have not achieved adequate blood glucose control, combination therapy is sometimes initiated. Sulfonylurea-sulfonylurea and various sulfonylurea-insulin regimens are discussed. The importance of diabetic patient education is reviewed, including some basic instructions pharmacists can give to diabetics. The investigation of other oral hypoglycemic agents continues. Information of selected agents undergoing clinical trials in the United States is also reviewed. Copyright © 1992 by W.B. Saunders Company

show abstract

Pharmacotherapy of Oral Hypoglycemic Agents

Miyahara

1992

Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Crossover Comparison of Maximum Dose Glyburide and Glipizide

Cited by 6 publications

References 0 publications

Long-Term Randomized Placebo-Controlled Double-Blind Therapeutic Comparison of Glipizide and Glyburide: Glycemic control and insulin secretion during 15 months

Long-Term Randomized Placebo-Controlled Double-Blind Therapeutic Comparison of Glipizide and Glyburide: Glycemic control and insulin secretion during 15 months

Pharmacotherapy of Oral Hypoglycemic Agents

Pharmacotherapy of Oral Hypoglycemic Agents

Contact Info

Product

Resources

About